The GoodRx announcement comes more than six months after Sanofi pledged to slash the list price of Lantus, establishing a $35 cap on out-of-pocket costs for patients living with diabetes.
Amazon Pharmacy automates coupons for $35 insulin, diabetes products
Amazon becomes the latest company to revise its approach to insulin in a year where major pharma brands have sought to cut costs for patients with diabetes.
‘Prices keep rising, yet there’s no transparency’: Senate panel targets drug costs
A Senate HELP Committee hearing left much to be desired when it comes to clarity on high drug prices. But some experts believe the needle is still shifting on change.
What you need to know about pharma, PBM execs testifying on insulin prices
The hearing was held less than two months after Sanofi, Novo Nordisk and Eli Lilly announced that they would cap the cost of insulin and drugs used by patients with diabetes.
California picks generic drug company Civica to produce low-cost insulin
Insulin has come to embody the perversity of the U.S. health care system as list prices for the century-old drug, which 8.4 million Americans depend on for survival, quintupled over two decades to more than $300 for a single vial.
Novo Nordisk and Sanofi face pressure to cut insulin prices following Eli Lilly’s move
